Laredo, Texas, June 26, 2019 — (TEXAS NEWSWIRE) The American Ophthalmologic Society of America (AOSA) today reported that a hospital in Louisiana has recalled OxyContin and oxycodones to treat a patient’s eye pain because the medications were used to treat an eye infection in his eye.AOSAs own medical staff reported that the patient was prescribed OxyContin to treat severe post-operative eye pain in his left eye.
OxyContin was purchased by the hospital for use in the treatment of severe postoperative eye infections.
The hospital reported that it has since withdrawn the oxycodoned medication.
The patient’s condition was described as “severe” and was reported to be critical.
According to the hospital, the patient’s wife received an injection of the oxycode over the phone on July 31, 2019.
The injection was administered at approximately 5:45 a.m. local time and the patient received an oxycodide dose of 3,200 mg per hour, which was followed by a dose of 200 mg daily.
The dosage was administered via a syringe.
The patient had a history of eye infections that were diagnosed by a team of ophthalmic ophthalmology specialists and other professionals and referred to the AOSA Medical Group, which then reviewed the information and made a recommendation to the Ophthalmology Department at the hospital.
The Ophthalmic Department promptly began the patient on a course of treatment, which included the use of a prescription medication for the treatment and prevention of eye infection.
The medication is an injectable oxycodepine-based medication that contains oxycodel and oxymorphone.
The Ophthalmia Department has received the patientís written and oral reports from the OVA’s Ophthalmedicine and Ophthalmoscope Unit, which include recommendations for the patient to continue to use the medication as directed by his or her ophthalmmologist.
The AOSAs Office of Medical Director will be notified of the findings.
A hospital spokesperson said that the hospital does not comment on pending investigations.